lifestyle.pspl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Structure Therapeutics Inc.
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
May 6, 2026
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
May 4, 2026
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
April 30, 2026
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
February 27, 2026